Alexander M. Lesokhin
Memorial Sloan Kettering Cancer Center
282 Papers
526 Citations
Alexander M. Lesokhin is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Medicine & Multiple myeloma. The author has an hindex of 33, co-authored 138 publications. Previous affiliations of Alexander M. Lesokhin include Cornell University & Bristol-Myers Squibb.
Chat about Author
Papers
MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy
Marion Eveillard,Marion Eveillard,Malin Hultcrantz,Alexander M. Lesokhin,Sham Mailankody,Eric L. Smith,Hani Hassoun,Urvi A Shah,Sydney X. Lu,Neha Korde,Ola Landgren,Katie L. Thoren +11 more
TL;DR: The performance of MALDI-TOF MS in the follow-up of newly diagnosed multiple myeloma patients treated with a daratumumab-based combination therapy is evaluated and the advantages and disadvantages of the technique are discussed.
2
P-275 CARTITUDE-1 final results: phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
S. Jagannath,Thomas Martin,Saad Z. Usmani,Jesus G. Berdeja,Andrzej Jakubowiak,Mounzer Agha,Adam Cohen,Abhinav Deol,Myo Htut,Alexander M. Lesokhin,Nikhil Munshi,Elizabeth O'Donnell,Carolyn C. Jackson,Tzu-min Yeh,Arnob Banerjee,Enrique Zudaire,Deepu Madduri,Christopher Delcorral,Lida Bubuteishvili Pacaud,Yi Lin +19 more
TL;DR: This phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma reports a 50% objective response rate, with 37.5% achieving complete response or better, and a manageable safety profile.
2
Using MALDI-TOF mass spectrometry for tracking of minimal residual disease in peripheral blood from patients with multiple myeloma.
Marion Eveillard,Even H Rustad,Mikhail Roshal,Yanming Zhang,Amanda Ciardiello,Neha Korde,Malin Hultcrantz,Hani Hassoun,Eric L. Smith,Alexander M. Lesokhin,Sham Mailankody,Carl Ola Landgren,Katie L. Thoren +12 more
TL;DR: This data indicates that suppression of minimal residual disease negativity after completed therapy is associated with longer progression-free survival (PFS) in patients with multiple myeloma.
2
P870: efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma and prior b-cell maturation antigen (bcma)-directed therapies: a pooled analysis from magnetismm studies
Salomon Manier,Alexander M. Lesokhin,Mohamad Mohty,Ruben Niesvizky,Christopher Maisel,Bertrand Arnulf,Sarah Larson,Asya Nina Varshavsky-Yanovsky,Xavier Leleu,Lionel Karlin,David H. Vesole,Nizar J. Bahlis,Carlos Fernández de Larrea,Noopur Raje,Eric P. Leip,Sharon Sullivan,Mohamed Elmeliegy,Andrea Viqueira,Ajay K. Nooka +18 more
TL;DR: In patients with relapsed/refractory multiple myeloma and prior BCMA-directed therapies, elranatamab monotherapy showed a 45.3% objective response rate, with 17.4% achieving complete response or better, and was well-tolerated with no new safety signals.
2
Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach
Matthew J. Pianko,Timothy Tiutan,Andriy Derkach,Jessica Flynn,F. Salvatore,Insara Jaffer-Sathick,Adriana C Rossi,Oscar B Lahoud,Malin Hultcrantz,Urvi A Shah,Kylee H Maclachlan,David J. Chung,Gunjan L. Shah,Heather Landau,Neha Korde,Sham Mailankody,Alexander M. Lesokhin,Carlyn Rose C. Tan,Michael Scordo,Edgar A. Jaimes,Sergio Giralt,Saad Usmani,Hani Hassoun +22 more
TL;DR: In this article , a retrospective analysis of renal outcomes among 34 patients with monoclonal immunoglobulin deposition disease (MIDD), often associated with plasma cell dyscrasias, predominantly affects the kidneys.
2